Bio-Path Holdings Inc. - התחייבויות לטווח ארוך של החברה BPTH

Bio-Path Holdings (BPTH) minimizes scientific risks by employing unique RNA methods in the development of leukemia and tumor treatments. The business model relies on external contractors for formula synthesis and testing, which eliminates the need for the firm to incur manufacturing plant costs. This chart of current market quotes shows debt at 0.00. Strict FDA oversight regarding molecule safety is slowing the expansion of this therapeutic niche.

Bio-Path Holdings (BPTH) develops anti-tumor RNA drugs while adhering to strict bioethics and ESG standards. An analysis of the corporation's long-term loans and borrowings allows for an assessment of the sustainability of this scientific model. This metric aggregates all obligations with a maturity of more than one year, measuring the issuer's financial autonomy. A reduction in the debt load confirms a margin of safety, although it limits the effect of financial leverage. This determines the actual investment reliability of the asset.